225 results on '"Punyadeera C"'
Search Results
2. Collection and determination of nucleotide metabolites in neonatal and adult saliva by high performance liquid chromatography with tandem mass spectrometry
- Author
-
Al-Shehri, S., Henman, M., Charles, B.G., Cowley, D., Shaw, P.N., Liley, H., Tomarchio, A., Punyadeera, C., and Duley, J.A.
- Published
- 2013
- Full Text
- View/download PDF
3. Clinical Applications of Circulating Tumour Cells and Circulating Tumour DNA in Non-Small Cell Lung Cancer-An Update
- Author
-
Kapeleris, J, Ebrahimi Warkiani, M, Kulasinghe, A, Vela, I, Kenny, L, Ladwa, R, O'Byrne, K, and Punyadeera, C
- Subjects
1112 Oncology and Carcinogenesis - Abstract
Despite efforts to improve earlier diagnosis of non-small cell lung cancer (NSCLC), most patients present with advanced stage disease, which is often associated with poor survival outcomes with only 15% surviving for 5 years from their diagnosis. Tumour tissue biopsy is the current mainstream for cancer diagnosis and prognosis in many parts of the world. However, due to tumour heterogeneity and accessibility issues, liquid biopsy is emerging as a game changer for both cancer diagnosis and prognosis. Liquid biopsy is the analysis of tumour-derived biomarkers in body fluids, which has remarkable advantages over the use of traditional tumour biopsy. Circulating tumour cells (CTCs) and circulating tumour DNA (ctDNA) are two main derivatives of liquid biopsy. CTC enumeration and molecular analysis enable monitoring of cancer progression, recurrence, and treatment response earlier than traditional biopsy through a minimally invasive liquid biopsy approach. CTC-derived ex-vivo cultures are essential to understanding CTC biology and their role in metastasis, provide a means for personalized drug testing, and guide treatment selection. Just like CTCs, ctDNA provides opportunity for screening, monitoring, treatment evaluation, and disease surveillance. We present an updated review highlighting the prognostic and therapeutic significance of CTCs and ctDNA in NSCLC.
- Published
- 2022
4. A pilot study for presence of circulating tumour cells in adenoid cystic carcinoma
- Author
-
Fisher, B.M., primary, Tang, K.D., additional, Warkiani, M.E., additional, Punyadeera, C., additional, and Batstone, M.D., additional
- Published
- 2021
- Full Text
- View/download PDF
5. A pilot study for presence of circulating tumour cells in adenoid cystic carcinoma
- Author
-
Fisher, BM, Tang, KD, Warkiani, ME, Punyadeera, C, and Batstone, MD
- Subjects
stomatognathic diseases ,Dentistry ,Humans ,1105 Dentistry ,Pilot Projects ,Neoplasm Recurrence, Local ,Neoplastic Cells, Circulating ,Prognosis ,Salivary Gland Neoplasms ,Carcinoma, Adenoid Cystic - Abstract
Adenoid cystic carcinoma (ACC) is a rare salivary gland neoplasm with a poor long-term prognosis due to multiple recurrences and distant metastatic spread. Circulating tumour cells (CTCs) are tumour cells shed from a primary, recurrent, or metastatic cancer that are detectable in the blood or lymphatics. There is no literature to date confirming the presence of CTCs in ACC. The aim of this study was to determine whether CTCs are detectable in ACC. Blood samples were collected from eight patients with histologically confirmed ACC. The TNM stage of the tumour was recorded, as well as any prior treatment. CTCs were isolated by spiral microfluidics and detected by immunofluorescence staining. Three of the eight patients recruited (32.5%) had staining consistent with the presence of CTCs. Of these three patients with detectable CTCs, one had confirmed pulmonary metastasis, one had suspected pulmonary metastasis and was awaiting confirmation, and one had local recurrence confirmed on re-resection. One patient with known isolated pulmonary metastasis had previously undergone a lung metastasectomy and did not have CTCs detected. CTCs are detectable in ACC. In this small patient sample, CTCs were found to be present in those patients with recurrent local disease and known distant metastatic disease. CTCs in ACC should be investigated further for their potential use as an adjunct in staging, prognosis, and the detection of recurrence.
- Published
- 2020
6. Three-dimensional flow-through protein platform
- Author
-
van Lieshout, R.M.L., van Domburg, T., Saalmink, M., Verbeek, R., Wimberger-Friedl, R., van Dieijen-Visser, M.P., and Punyadeera, C.
- Subjects
Protein microarrays -- Materials ,Protein microarrays -- Technology application ,Technology application ,Chemistry - Abstract
We have developed a new protein microarray (Immuno-Flow Protein Platform, IFPP) that utilizes a porous nitrocellulose (NC) membrane with printed spots of capture probes. The sample is pumped actively through the NC membrane, to enhance binding efficiency and introduce stringency. Compared to protein microarrays assayed with the conventional incubation--shaking method the rate of binding is enhanced on the IFPP by at least a factor of 10, so that the total assay time can be reduced drastically without compromising sensitivity. Similarly, the sensitivity can be improved. We demonstrate the detection of 1 pM of C-reactive protein (CRP) in 70 [micro]L of plasma within a total assay time of 7 min. The small sample and reagent volumes, combined with the speed of the assay, make our IFPP also well-suited for a point-of-care/near-patient setting. The potential clinical application of the IFPP is demonstrated by validating CRP detection both in human plasma and serum samples against standard clinical laboratory methods.
- Published
- 2009
7. Progesterone regulation of implantation-related genes: new insights into the role of oestrogen
- Author
-
Dassen, H., Punyadeera, C., Kamps, R., Klomp, J., Dunselman, G., Dijcks, F., de Goeij, A., Ederveen, A., and Groothuis, P.
- Published
- 2007
- Full Text
- View/download PDF
8. Oestrogen-modulated gene expression in the human endometrium
- Author
-
Punyadeera, C., Dassen, H., Klomp, J., Dunselman, G., Kamps, R., Dijcks, F., Ederveen, A., de Goeij, A., and Groothuis, P.
- Published
- 2005
- Full Text
- View/download PDF
9. Haemoglobin expression in human endometrium
- Author
-
Dassen, H., Kamps, R., Punyadeera, C., Dijcks, F., de Goeij, A., Ederveen, A., Dunselman, G., and Groothuis, P.
- Published
- 2008
10. Identification of novel antigens in blood vessels in rectovaginal endometriosis
- Author
-
Van Langendonckt, A., Punyadeera, C., Kamps, R., Dunselman, G., Klein-Hitpass, L., Schurgers, L.J., Squifflet, J., Donnez, J., and Groothuis, P.
- Published
- 2007
11. Estrogen metabolizing enzymes in endometrium and endometriosis
- Author
-
Dassen, H., Punyadeera, C., Kamps, R., Delvoux, B., Van Langendonckt, A., Donnez, J., Husen, B., Thole, H., Dunselman, G., and Groothuis, P.
- Published
- 2007
12. Estrogen and the endometrium: lessons learned from gene expression profiling in rodents and human
- Author
-
Groothuis, P.G., Dassen, H.H.N.M., Romano, A., and Punyadeera, C.
- Published
- 2007
13. Expression and regulation of vascular endothelial growth factor ligands and receptors during menstruation and post-menstrual repair of human endometrium
- Author
-
Punyadeera, C., Thijssen, V.L., Tchaikovski, S., Kamps, R., Delvoux, B., Dunselman, G.A.J., de Goeij, A.F.P.M., Griffioen, A.W., and Groothuis, P.G.
- Published
- 2006
14. Menstrual effluent induces epithelial–mesenchymal transitions in mesothelial cells
- Author
-
Demir, A.Y., Groothuis, P.G., Nap, A.W., Punyadeera, C., de Goeij, A.F.P.M., Evers, J.L.H., and Dunselman, G.A.J.
- Published
- 2004
15. Unlocking the potential of saliva-based test to detect HPV-driven oropharyngeal cancer
- Author
-
Tang, K.D., primary and Punyadeera, C., additional
- Published
- 2018
- Full Text
- View/download PDF
16. ACKNOWLEDGEMENT OF REVIEWERS
- Author
-
Adams, NG, Adekambi, T, Afeltra, J, Aguado, J, Aires de Sousa, M, Akiyoshi, K, Al Hasan, M, Ala-Kokko, T, Albert, M, Alfandari, S, Allen, D, Allerberger, F, Almyroudis, N, Alp, E, Amin, R, Anderson-Berry, A, Andes, DR, Andremont, A, Andreu, A, Angelakis, M, Antachopoulos, C, Antoniadou, A, Arabatzis, M, Arlet, G, Arnez, M, Arnold, C, Asensio, A, Asseray, N, Ausiello, C, Avni, T, Ayling, R, Baddour, L, Baguelin, M, Bányai, K, Barbour, A, Basco, LK, Bauer, D, Bayston, R, Beall, B, Becker, K, Behr, M, Bejon, P, Belliot, G, Benito-Fernandez, J, Benjamin, D, Benschop, K, Berencsi, G, Bergeron, MG, Bernard, K, Berner, R, Beyersmann, J, Bille, J, Bizzini, A, Bjarnsholt, T, Blanc, D, Blanco, J, Blot, S, Bohnert, J, Boillat, N, Bonomo, R, Bonten, M, Bordon, JM, Borel, N, Boschiroli, ML, Bosilkovski, M, Bosso, JA, Botelho-Nevers, E, Bou, G, Bretagne, S, Brouqui, P, Brun-Buisson, C, Brunetto, M, Bucher, H, Buchheidt, D, Buckling, A, Bulpa, P, Cambau, E, Canducci, F, Cantón, R, Capobianchi, M, Carattoli, A, Carcopino, X, Cardona-Castro, N, Carling, PC, Carrat, F, Castilla, J, Castilletti, C, Cavaco, L, Cavallo, R, Ceccherini-Silberstein, F, Centrón, D, Chappuis, F, Charrel, R, Chen, M, Chevaliez, S, Chezzi, C, Chomel, B, Chowers, M, Chryssanthou, E, Ciammaruconi, A, Ciccozzi, M, Cid, J, Ciofu, O, Cisneros, D, Ciufolini, MG, Clark, C, Clarke, SC, Clayton, R, Clementi, M, Clemons, K, Cloeckaert, Ael, Cloud, J, Coenye, T, Cohen Bacri, S, Cohen, R, Coia, J, Colombo, A, Colson, P, Concerse, P, Cordonnier, C, Cormican, M, Cornaglia, G, Cornely, O, Costa, S, Cots, F, Craxi, A, Creti, R, Crnich, C, Cuenca Estrella, M, Cusi, MG, d'Ettorre, G, da Cruz Lamas, C, Daikos, G, Dannaoui, E, De Barbeyrac, B, De Grazia, S, de Jager, C, de Lamballerie, X, de Marco, F, del Palacio, A, Delpeyroux, F, Denamur, E, Denis, O, Depaquit, J, Deplano, A, Desenclos, J-C, Desjeux, P, Deutch, S, Di Luca, D, Dianzani, F, Diep, B, Diestra, K, Dignani, C, Dimopoulos, G, Divizia, M, Doi, Y, Dornbusch, HJ, Dotis, J, Drancourt, M, Drevinek, P, Dromer, F, Dryden, M, Dubreuil, L, Dubus, J-C, Dumitrescu, O, Dumke, R, DuPont, H, Edelstein, M, Eggimann, P, Eis-Huebinger, A-M, El Atrouni, WI, Entenza, J, Ergonul, O, Espinel-Ingroff, A, Esteban, J, Etienne, J, Fan, X-G, Fenollar, F, Ferrante, P, Ferrieri, P, Ferry, T, Feuchtinger, T, Finegold, S, Fingerle, V, Fitch, M, Fitzgerald, R, Flori, P, Fluit, A, Fontana, R, Fournier, PE, François, M, Francois, P, Freedman, DO, Friedrich, A, Gallego, L, Gallinella, G, Gangneux, J-P, Gannon, V, Garbarg-Chenon, A, Garbino, J, Garnacho-Montero, J, Gatermann, Soeren, Gautret, P, Gentile, G, Gerlich, W, Ghannoum, M, Ghebremedhin, B, Ghigo, E, Giamarellos-Bourboulis, E, Girgis, R, Giske, C, Glupczynski, Y, Gnarpe, J, Gomez-Barrena, E, Gorwitz, RJ, Gosselin, R, Goubau, P, Gould, E, Gradel, K, Gray, J, Gregson, D, Greub, G, Grijalva, CG, Groll, A, Groschup, M, Gutiérrez, J, Hackam, DG, Hall, WA, Hallett, R, Hansen, S, Harbarth, S, Harf-Monteil, C, Hasanjani, Roushan MR, Hasler, P, Hatchette, T, Hauser, P, He, Q, Hedges, A, Helbig, J, Hennequin, C, Herrmann, B, Hezode, C, Higgins, P, Hoesli, I, Hoiby, N, Hope, W, Houvinen, P, Hsu, LY, Huard, R, Humphreys, H, Icardi, M, Imoehl, M, Ivanova, K, Iwamoto, T, Izopet, J, Jackson, Y, Jacobsen, K, Jang, TN, Jasir, A, Jaulhac, B, Jaureguy, F, Jefferies, JM, Jehl, F, Johnstone, J, Joly-Guillou, M-L, Jonas, M, Jones, M, Joukhadar, C, Kahl, B, Kaier, K, Kaiser, L, Kato, H, Katragkou, A, Kearns, A, Kern, W, Kerr, K, Kessin, R, Kibbler, C, Kimberlin, D, Kittang, B, Klaassen, C, Kluytmans, J, Ko, W-C, Koh, W-J, Kostrzewa, M, Kourbeti, I, Krause, R, Krcmery, V, Krizova, P, Kuijper, E, Kullberg, B-J, Kumar, G, Kunin, CM, La Scola, B, Lagging, M, Lagrou, K, Lamagni, T, Landini, P, Landman, D, Larsen, A, Lass-Floerl, C, Laupland, K, Lavigne, JP, Leblebicioglu, H, Lee, B, Lee, CH, Leggat, P, Lehours, P, Leibovici, Lonard, Leon, L, Leonard, N, Leone, M, Lescure, X, Lesprit, P, Levy, PY, Lew, D, Lexau, CA, Li, S-Y, Li, W, Lieberman, D, Lina, B, Lina, G, Lindsay, JA, Livermore, D, Lorente, L, Lortholary, O, Lucet, J-C, Lund, B, Lütticken, R, MacLeod, C, Madhi, S, Maertens, J, Maggi, F, Maiden, M, Maillard, J-Y, Maira-Litran, T, Maltezou, H, Manian, FA, Mantadakis, E, Maragakis, L, Marcelin, A-G, Marchaim, D, Marchetti, O, Marcos, M, Markotic, A, Martina, B, Martínez, J, Martinez, J-L, Marty, F, Maurin, M, McGee, L, Mediannikov, O, Meersseman, W, Megraud, F, Meletiadis, J, Mellmann, A, Meyer, E, Meyer, W, Meylan, P, Michalopoulos, A, Micol, R, Midulla, F, Mikami, Y, Miller, RF, Miragaia, M, Miriagou, V, Mitchell, TJ, Miyakis, S, Mokrousov, I, Monecke, S, Mönkemüller, K, Monno, L, Monod, M, Morales, G, Moriarty, F, Morosini, I, Mortensen, E, Mubarak, K, Mueller, B, Mühlemann, K, Muñoz Bellido, JL, Murray, P, Muscillo, M, Mylotte, J, Naessens, A, Nagy, E, Nahm, MH, Nassif, X, Navarro, D, Navarro, F, Neofytos, D, Nes, I, Ní Eidhin, D, Nicolle, L, Niederman, MS, Nigro, G, Nimmo, G, Nordmann, P, Nougairède, A, Novais, A, Nygard, K, Oliveira, D, Orth, D, Ortiz, JR, Osherov, N, Österblad, M, Ostrosky-Zeichner, L, Pagano, L, Palamara, AT, Pallares, R, Panagopoulou, P, Pandey, P, Panepinto, J, Pappas, G, Parkins, M, Parola, P, Pasqualotto, A, Pasteran, F, Paul, M, Pawlotsky, J-M, Peeters, M, Peixe, L, Pepin, J, Peralta, G, Pereyre, S, Perfect, JR, Petinaki, E, Petric, M, Pettigrew, M, Pfaller, M, Philipp, M, Phillips, G, Pichichero, M, Pierangeli, A, Pierard, D, Pigrau, C, Pilishvili, T, Pinto, F, Pistello, M, Pitout, J, Poirel, L, Poli, G, Poppert, S, Posfay-Barbe, K, Pothier, P, Poxton, I, Poyart, C, Pozzetto, B, Pujol, M, Pulcini, C, Punyadeera, C, Ramirez, M, Ranque, S, Raoult, D, Rasigade, J-P, Re, MC, Reilly, JS, Reinert, R, Renaud, B, Rice, L, Rich, S, Richet, H, Rigouts, L, Riva, E, Rizzo, C, Robotham, J, Rodicio, MR, Rodriguez, J, Rodriguez-Bano, J, Rogier, C, Roilides, E, Rolain, J-M, Rooijakkers, S, Rooney, P, Rossi, F, Rotimi, V, Rottman, M, Roux, V, Ruhe, J, Russo, G, Sadowy, E, Sagel, U, Said, SI, Saijo, M, Sak, B, Sa-Leao, R, Sanders, EAM, Sanguinetti, M, Sarrazin, C, Savelkoul, P, Scheifele, D, Schmidt, W-P, Schønheyder, H, Schönrich, G, Schrenzel, J, Schubert, S, Schwarz, K, Schwarz, S, Sefton, A, Segondy, M, Seifert, H, Seng, P, Senneville, E, Sexton, D, Shafer, RW, Shalit, I, Shankar, N, Shata, TM, Shields, J, Sibley, C, Sicinschi, L, Siljander, T, Simitsopoulou, M, Simoons-Smit, AM, Sissoko, D, Sjögren, J, Skiada, A, Skoczynska, A, Skov, R, Slack, M, Sogaard, M, Sola, C, Soriano, A, Sotto, A, Sougakoff, W, Souli, M, Spelberg, B, Spelman, D, Spiliopoulou, I, Springer, B, Stefani, S, Stein, A, Steinbach, WJ, Steinbakk, M, Strakova, L, Strenger, V, Sturm, P, Sullivan, P, Sutton, D, Symmons, D, Tacconelli, E, Tamalet, C, Tang, JW, Tang, Y-W, Tattevin, P, Thibault, V, Thomsen, RW, Thuny, F, Tong, S, Torres, C, Townsend, R, Tristan, A, Trouillet, J-L, Tsai, H-C, Tsitsopoulos, P, Tuerlinckx, D, Tulkens, P, Tumbarello, M, Tureen, J, Turnidge, JD, Turriziani, O, Tutuian, R, Uçkay, I, Upton, M, Vabret, A, Vamvakas, EC, van den Boom, D, Van Eldere, J, van Leeuwen, W, van Strijp, J, Van Veen, S, Vandamme, P, Vandenesch, F, Vayssier, M, Velin, D, Venditti, M, Venter, M, Venuti, A, Vergnaud, G, Verheij, T, Verhofstede, C, Viscoli, C, Vizza, CD, Vogel, U, Waller, A, Wang, YF, Warn, P, Warris, A, Wauters, G, Weidmann, M, Weill, F-X, Weinberger, M, Welch, D, Wellinghausen, N, Wheat, J, Widmer, A, Wild, F, Willems, R, Willinger, B, Winstanley, C, Witte, W, Wolff, M, Wong, F, Wootton, M, Wyllie, D, Xu, W, Yamamoto, S, Yaron, S, Yildirim, I, Zaoutis, T, Zazzi, M, Zbinden, R, Zehender, Gianguglielmo G, Zemlickova, H, Zerbini, ML, Zhang, L, Zhang, Y, Zhao, Y-D, Zhu, Z, and Zimmerli, W
- Published
- 2011
- Full Text
- View/download PDF
17. Short term ex-vivo expansion of circulating head and neck tumour cells
- Author
-
Kulasinghe, A, Perry, C, Warkiani, ME, Blick, T, Davies, A, O'Byrne, K, Thompson, EW, Nelson, CC, Vela, I, and Punyadeera, C
- Subjects
Aged, 80 and over ,Male ,Time Factors ,Cell Culture Techniques ,Cell Count ,Pilot Projects ,Middle Aged ,Neoplastic Cells, Circulating ,ErbB Receptors ,Head and Neck Neoplasms ,Tumor Cells, Cultured ,Humans ,1112 Oncology and Carcinogenesis ,Female ,In Situ Hybridization, Fluorescence ,Aged ,Cell Proliferation - Abstract
Minimally invasive techniques are required for the identification of head and neck cancer (HNC) patients who are at an increased risk of metastasis, or are not responding to therapy. An approach utilised in other solid cancers is the identification and enumeration of circulating tumour cells (CTCs) in the peripheral blood of patients. Low numbers of CTCs has been a limiting factor in the HNC field to date. Here we present a methodology to expand HNC patient derived CTCs ex-vivo. As a proof of principle study, 25 advanced stage HNC patient bloods were enriched for circulating tumour cells through negative selection and cultured in 2D and 3D culture environments under hypoxic conditions (2% O2, 5% CO2). CTCs were detected in 14/25 (56%) of patients (ranging from 1-15 CTCs/5 mL blood). Short term CTC cultures were successfully generated in 7/25 advanced stage HNC patients (5/7 of these cultures were from HPV+ patients). Blood samples from which CTC culture was successful had higher CTC counts (p = 0.0002), and were predominantly from HPV+ patients (p = 0.007). This is, to our knowledge, the first pilot study to culture HNC CTCs ex-vivo. Further studies are warranted to determine the use of short term expansion in HNC and the role of HPV in promoting culture success.
- Published
- 2016
18. MicroRNAs in HPV associated cancers: small players with big consequences
- Author
-
Satapathy, Sandeep, primary, Batra, Jyotsna, additional, Jeet, Varinder, additional, Thompson, Erik W., additional, and Punyadeera, C., additional
- Published
- 2017
- Full Text
- View/download PDF
19. 328P - Unlocking the potential of saliva-based test to detect HPV-driven oropharyngeal cancer
- Author
-
Tang, K.D. and Punyadeera, C.
- Published
- 2018
- Full Text
- View/download PDF
20. A Simple Saliva Test to Diagnose Heart Failure
- Author
-
Foo, J., primary, Kostner, K., additional, Chen, C., additional, Schulz, B., additional, Cooper-White, J., additional, Wan, Y., additional, Eng, L., additional, Arivalagan, A., additional, and Punyadeera, C., additional
- Published
- 2012
- Full Text
- View/download PDF
21. Effects of selective oestrogen receptor modulators on proliferation in tissue cultures of pre- and postmenopausal human endometrium
- Author
-
Punyadeera, C., primary, Kamps, R., additional, Defrère, S., additional, Dijcks, F., additional, de Goeij, A., additional, Ederveen, A., additional, Dunselman, G., additional, and Groothuis, P., additional
- Published
- 2008
- Full Text
- View/download PDF
22. Triphasic pattern in the ex vivo response of human proliferative phase endometrium to oestrogens
- Author
-
Punyadeera, C., primary, Dunselman, G., additional, Marbaix, E., additional, Kamps, R., additional, Galant, C., additional, Nap, A., additional, Goeij, A. de, additional, Ederveen, A., additional, and Groothuis, P., additional
- Published
- 2004
- Full Text
- View/download PDF
23. Oestrogen and progestin responses in human endometrium
- Author
-
Punyadeera, C., primary, Verbost, P., additional, and Groothuis, P., additional
- Published
- 2003
- Full Text
- View/download PDF
24. Weight-related differences in glucose metabolism and free fatty acid production in two South African population groups
- Author
-
Punyadeera, C, primary, van der Merwe, M-T, additional, Crowther, NJ, additional, Toman, M, additional, Immelman, AR, additional, Schlaphoff, GP, additional, and Gray, IP, additional
- Published
- 2001
- Full Text
- View/download PDF
25. AN ENHANCED PROCEDURE FOR THE RAPID DIGESTION OF HIGH SILICATE ARCHEOLOGICAL SPECIMENS FOLLOWED BY ICP-MS DETERMINATION OF TRACES OF RARE EARTH ELEMENTS (REE's)
- Author
-
Pillay, A. E., primary and Punyadeera, C., additional
- Published
- 2001
- Full Text
- View/download PDF
26. A STUDY, BY FIRE-ASSAY AND ICP-MS, OF THE DISTRIBUTION OF RHODIUM, PLATINUM, AND GOLD IN IRON-AGE POTTERY
- Author
-
Pillay, A. E., primary and Punyadeera, C., additional
- Published
- 2001
- Full Text
- View/download PDF
27. Ethnic differences in lipid metabolism in two groups of obese South African women
- Author
-
Punyadeera, C., primary, van der Merwe, M-T., additional, Crowther, N.J., additional, Toman, M., additional, Schlaphoff, G.P., additional, and Gray, I.P., additional
- Published
- 2001
- Full Text
- View/download PDF
28. Analysis of ancient pottery and ceramic objects using x-ray fluorescence spectrometry
- Author
-
Pillay, A. E., primary, Punyadeera, C., additional, Jacobson, L., additional, and Eriksen, J., additional
- Published
- 2000
- Full Text
- View/download PDF
29. Application of XRF and Correspondence Analysis to Provenance Studies of Coastal and Inland Archaeological Pottery from the Mngeni River Area, South Africa
- Author
-
Punyadeera, C., primary, Pillay, A. E., additional, Jacobson, L., additional, and Whitelaw, G., additional
- Published
- 1997
- Full Text
- View/download PDF
30. A biomarker panel to discriminate between systemic inflammatory response syndrome and sepsis and sepsis severity
- Author
-
Punyadeera Chamindie, Schneider E, Schaffer Dave, Hsu Hsin-Yun, Joos Thomas, Kriebel Fabian, Weiss Manfred, and Verhaegh Wim
- Subjects
Biomarker ,cellular mechanism ,sepsis outcome ,SIRS ,sepsis stage ,Medical emergencies. Critical care. Intensive care. First aid ,RC86-88.9 - Abstract
Introduction: In this study, we report on initial efforts to discover putative biomarkers for differential diagnosis of a systemic inflammatory response syndrome (SIRS) versus sepsis; and different stages of sepsis. In addition, we also investigated whether there are proteins that can discriminate between patients who survived sepsis from those who did not. Materials and Methods: Our study group consisted of 16 patients, of which 6 died and 10 survived. We daily measured 28 plasma proteins, for the whole stay of the patients in the ICU. Results: We observed that metalloproteinases and sE-selectin play a role in the distinction between SIRS and sepsis, and that IL-1α, IP-10, sTNF-R2 and sFas appear to be indicative for the progression from sepsis to septic shock. A combined measurement of MMP-3, -10, IL-1α, IP-10, sIL-2R, sFas, sTNF-R1, sRAGE, GM-CSF, IL-1β and Eotaxin allows for a good separation of patients that survived from those that died (mortality prediction with a sensitivity of 79% and specificity of 86%). Correlation analysis suggests a novel interaction between IL-1a and IP-10. Conclusion: The marker panel is ready to be verified in a validation study with or without therapeutic intervention
- Published
- 2010
31. Diagnostic potential of saliva: State of the art and future applications,Potenziale diagnostico della saliva: Stato dell'arte e applicazioni future
- Author
-
Pfaffe, T., Justin Cooper-White, Beyerlein, P., Kostner, K., and Punyadeera, C.
32. Current trends and management in head and neck cancers
- Author
-
Kulasinghe, A., Yenkai Lim, Perry, C. F. L., and Punyadeera, C.
33. Authors′ reply
- Author
-
Punyadeera Chamindie, Schneider Marion, Schaffer Dave, Hsu Hsin-Yun, Joos Thomas, Kriebel Fabian, Weiss Manfred, and Verhaegh Wim
- Subjects
Medical emergencies. Critical care. Intensive care. First aid ,RC86-88.9 - Published
- 2010
34. The potential of hydrogel-free tumoroids in head and neck squamous cell carcinoma.
- Author
-
Wong M, Vasani S, Breik O, Zhang X, Kenny L, and Punyadeera C
- Subjects
- Humans, Animals, Tumor Microenvironment, Organoids pathology, Laminin, Mice, Drug Combinations, Proteoglycans metabolism, Collagen metabolism, Squamous Cell Carcinoma of Head and Neck pathology, Head and Neck Neoplasms pathology, Hydrogels chemistry
- Abstract
Background: Head and neck malignancy, and in particular squamous cell carcinoma (SCC), is responsible for a significant disease burden globally. The lack of an optimal in vitro model system to accurately recapitulate in vivo response to therapy in HNSCC remains a challenge. The development of patient-derived three-dimensional tumour cultures, or tumoroids, has enabled improved modelling of the tumour microenvironment through simulation of important characteristics such as tumour hypoxia, cell-cell interactions and nutrient diffusion characteristics., Methods: We performed a comprehensive English-language literature review of current methods of tumoroid development utilising Matrigel and Cultrex Basement Membrane Extract 2 (key terms: tumour organoids, tumoroids, hydrogels, Matrigel, Cultrex, squamous cell carcinoma, head and neck)-two common proprietary murine-derived hydrogels containing extracellular matrix proteins. Nascent literature on the establishment of a novel hydrogel-free platform for tumoroid development as distinct from these existing methods was also explored., Results: Whilst useful for facilitating cell-matrix interactions and providing a scaffold for three-dimensional cell growth and organisation, murine-derived cell matrix methods were noted to have notable limitations including temperature sensitivity and the medium forming a barrier to analysis of the supernatant. A novel hydrogel-free method of establishing in vitro tumoroid cultures has been subject to experimentation in colorectal but not head and neck malignancy. The absence of a hydrogel provides for the de novo synthesis of extracellular matrix native to the tumour and self-organisation of cells within this scaffold through the use of ultralow attachment plates. This model demonstrates similar structural and physiological properties to native tissue, whilst enabling more accurate biomimicry of the tumour microenvironment for drug testing., Conclusions: In the absence of prior experimentation on a hydrogel-free method for establishing HNSCC tumoroids, and comparisons between hydrogel and hydrogel-free models, the future development of a comparative protocol encompassing recruitment, collection, processing and analysis represents a valuable opportunity., (© 2024 The Author(s). Cancer Medicine published by John Wiley & Sons Ltd.)
- Published
- 2024
- Full Text
- View/download PDF
35. Paper electrochemical immunosensor for the rapid screening of Galectin-3 patients with heart failure.
- Author
-
Nihal S, Sarfo D, Zhang X, Tesfamichael T, Karunathilaka N, Punyadeera C, and Izake EL
- Subjects
- Humans, Immunoassay methods, Saliva chemistry, Biomarkers analysis, Gold chemistry, Galectins analysis, Limit of Detection, Heart Failure diagnosis, Electrochemical Techniques, Paper, Biosensing Techniques methods, Galectin 3 analysis, Blood Proteins
- Abstract
A paper electrochemical immunosensor for the combined binding and quantification of the heart failure (HF) biomarker Galectin-3 has been developed. The simple design of the new sensor is comprised of paper material that is decorated with gold nanostructures, to maximize its electroactive surface area, and functionalized with target-specific recognition molecules to selectively bind the protein from aqueous solutions. The binding of the protein caused the blockage of the electron flow to the sensor electroactive surface, thus causing its oxidation potential to shift and the corresponding current to reduce quantitatively with the increase in the protein concentration within the working range of 0.5ng/mL-8ng/mL (LOQ-0.5 ng/mL). This novel sensor was able to quantify Galectin-3 concentration in saliva samples from HF patients and healthy controls within 20 min with good reproducibility (RSD = 3.64%), without the need for complex sample processing steps. The electrochemical measurements of the patient samples were cross validated by ELISA where the percent agreement between the two methods was found to be 92.7% (RSD = 7.20%). Therefore, the new paper immunosensor sensor has a strong potential for rapid and cost-effective screening of the Galectin 3 biomarker at points of care, thus supporting the timely diagnosis of heart failure., Competing Interests: Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (Copyright © 2024 The Authors. Published by Elsevier B.V. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
36. Surveillance of human papillomavirus through salivary diagnostics - A roadmap to early detection of oropharyngeal cancer in men.
- Author
-
Wijesekera A, Weeramange CE, Vasani S, Kenny L, Knowland E, Seneviratne J, and Punyadeera C
- Subjects
- Humans, Male, Papillomaviridae isolation & purification, Risk Factors, Human Papillomavirus Viruses, Oropharyngeal Neoplasms virology, Oropharyngeal Neoplasms diagnosis, Oropharyngeal Neoplasms epidemiology, Papillomavirus Infections diagnosis, Papillomavirus Infections epidemiology, Papillomavirus Infections virology, Early Detection of Cancer methods, Saliva virology
- Abstract
Human papillomavirus (HPV) is the most common sexually transmitted disease. Certain strains have the potential to cause malignancy in multiple anatomical sites if not cleared by the immune system. In most infected people, HPV is cleared within two years. However, HPV may persist in susceptible individuals with certain risk factors, eventually leading to malignancy. New evidence suggests that over 75% of all oropharyngeal cancers (OPC) are directly attributable to HPV. It is estimated that prophylactic HPV vaccination alone may take at least 25 years to have a significant impact on reducing the incidence of OPC. The temporal link between detection of oral HPV, persistence of the infection and the subsequent development of OPC have been well established. Moreover, men have threefold higher risk than women for acquiring HPV-OPC. This comprehensive review focuses on OPC development in men, highlighting the risk factors associated with malignant transformation of HPV-OPC. Current evidence is insufficient to determine whether early identification of at-risk demographics, screening, and prompt diagnosis result in improved outcomes. Hitherto, the effectiveness of an oral HPV screening program in this regard has not been investigated. Nevertheless, the potential to emulate the success of the cervical screening program remains a very real possibility., Competing Interests: Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (Copyright © 2024 The Authors. Published by Elsevier B.V. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
37. Circulating tumour cells predict recurrences and survival in head and neck squamous cell carcinoma patients.
- Author
-
Zhang X, Weeramange CE, Hughes BGM, Vasani S, Liu ZY, Warkiani M, Hartel G, Ladwa R, Thiery JP, Kenny L, Breik O, and Punyadeera C
- Subjects
- Humans, Male, Female, Middle Aged, Aged, Prognosis, Adult, Follow-Up Studies, Neoplastic Cells, Circulating pathology, Neoplastic Cells, Circulating metabolism, Head and Neck Neoplasms pathology, Head and Neck Neoplasms mortality, Head and Neck Neoplasms blood, Head and Neck Neoplasms diagnosis, Neoplasm Recurrence, Local pathology, Squamous Cell Carcinoma of Head and Neck pathology, Squamous Cell Carcinoma of Head and Neck mortality, Squamous Cell Carcinoma of Head and Neck blood, Squamous Cell Carcinoma of Head and Neck diagnosis, Carcinoma, Squamous Cell pathology, Carcinoma, Squamous Cell mortality, Carcinoma, Squamous Cell blood, Carcinoma, Squamous Cell diagnosis
- Abstract
Patients with head and neck squamous cell carcinoma (HNSCC) are at a high risk of developing recurrence and secondary cancers. This study evaluates the prognostic and surveillance utilities of circulating tumour cells (CTCs) in HNSCC. A total of 154 HNSCC patients were recruited and followed up for 4.5 years. Blood samples were collected at baseline and follow-up. CTCs were isolated using a spiral microfluid device. Recurrence and death due to cancer were assessed during the follow-up period. In patients with HNSCC, the presence of CTCs at baseline was a predictor of recurrence (OR = 8.40, p < 0.0001) and death (OR= ∞, p < 0.0001). Patients with CTCs at baseline had poor survival outcomes (p < 0.0001). Additionally, our study found that patients with CTCs in a follow-up appointment were 2.5 times more likely to experience recurrence or death from HNSCC (p < 0.05) prior to their next clinical visit. Our study highlights the prognostic and monitoring utilities of CTCs' in HNSCC patients. Early identification of CTCs facilitates precise risk assessment, guiding treatment choices and ultimately enhancing patient outcomes., (© 2024. The Author(s).)
- Published
- 2024
- Full Text
- View/download PDF
38. Human papillomavirus (HPV) DNA methylation changes in HPV-associated head and neck cancer.
- Author
-
Ekanayake Weeramange C, Tang KD, Irwin D, Hartel G, Langton-Lockton J, Ladwa R, Kenny L, Taheri T, Whitfield B, Vasani S, and Punyadeera C
- Subjects
- Female, Humans, DNA Methylation genetics, DNA, Viral genetics, Biomarkers analysis, Human Papillomavirus Viruses, Papillomaviridae genetics, Papillomavirus Infections genetics, Head and Neck Neoplasms genetics
- Abstract
Despite the rising incidence, currently, there are no early detection methods for HPV-driven HNC (HPV-HNC). Cervical cancer studies suggest that HPV DNA methylation changes can be used as a biomarker to discriminate cancer patients from HPV-infected individuals. As such, this study was designed to establish a protocol to evaluate DNA methylation changes in HPV late genes and long control region (LCR) in saliva samples of HPV-HNC patients and HPV-positive controls. Higher methylation levels were detected in HPV late genes (L1 and L2) in both tumour and saliva samples of HPV-HNC patients compared with HPV-positive controls. Moreover, methylation patterns between tumours and corresponding saliva samples were observed to have a strong correlation (Passing-Bablok regression analysis; τ = 0.7483, P < 0.0001). Considering the differences between HNC and controls in methylation levels in late genes, and considering primer amplification efficiencies, 13 CpG sites located at L1 and L2 genes were selected for further evaluation. A total of 18 HNC saliva samples and 10 control saliva samples were assessed for the methylation levels in the selected sites. From the CpG sites evaluated statistically significant differences were identified for CpG sites at L2-CpG 6 (P = 0.0004), L1-CpG 3 (P = 0.0144), L1-CpG 2 (P = 0.0395) and L2-CpG 19 (P = 0.0455). Our pilot data indicate that higher levels of DNA methylation in HPV late genes are indicative of HPV-HNC risk, and it is a potential supplementary biomarker for salivary HPV detection-based HPV-HNC screening., (© The Author(s) 2024. Published by Oxford University Press.)
- Published
- 2024
- Full Text
- View/download PDF
39. A novel saliva-based miRNA profile to diagnose and predict oral cancer.
- Author
-
Balakittnen J, Ekanayake Weeramange C, Wallace DF, Duijf PHG, Cristino AS, Hartel G, Barrero RA, Taheri T, Kenny L, Vasani S, Batstone M, Breik O, and Punyadeera C
- Subjects
- Humans, Saliva, Biomarkers, Tumor genetics, MicroRNAs genetics, Mouth Neoplasms diagnosis, Mouth Neoplasms genetics, Head and Neck Neoplasms, Precancerous Conditions
- Abstract
Oral cancer (OC) is the most common form of head and neck cancer. Despite the high incidence and unfavourable patient outcomes, currently, there are no biomarkers for the early detection of OC. This study aims to discover, develop, and validate a novel saliva-based microRNA signature for early diagnosis and prediction of OC risk in oral potentially malignant disorders (OPMD). The Cancer Genome Atlas (TCGA) miRNA sequencing data and small RNA sequencing data of saliva samples were used to discover differentially expressed miRNAs. Identified miRNAs were validated in saliva samples of OC (n = 50), OPMD (n = 52), and controls (n = 60) using quantitative real-time PCR. Eight differentially expressed miRNAs (miR-7-5p, miR-10b-5p, miR-182-5p, miR-215-5p, miR-431-5p, miR-486-3p, miR-3614-5p, and miR-4707-3p) were identified in the discovery phase and were validated. The efficiency of our eight-miRNA signature to discriminate OC and controls was: area under curve (AUC): 0.954, sensitivity: 86%, specificity: 90%, positive predictive value (PPV): 87.8% and negative predictive value (NPV): 88.5% whereas between OC and OPMD was: AUC: 0.911, sensitivity: 90%, specificity: 82.7%, PPV: 74.2% and NPV: 89.6%. We have developed a risk probability score to predict the presence or risk of OC in OPMD patients. We established a salivary miRNA signature that can aid in diagnosing and predicting OC, revolutionising the management of patients with OPMD. Together, our results shed new light on the management of OC by salivary miRNAs to the clinical utility of using miRNAs derived from saliva samples., (© 2024. The Author(s).)
- Published
- 2024
- Full Text
- View/download PDF
40. Electrochemical Immunosensor for the Quantification of Galectin-3 in Saliva.
- Author
-
Pittman TW, Zhang X, Punyadeera C, and Henry CS
- Abstract
Heart failure (HF) is an emerging epidemic and remains a major clinical and public health problem. Advances in the healthcare management of HF may lead to lower morbidity and mortality rates but require diagnostics to guide the process. Current diagnostics/prognostics approaches rely on expensive equipment, centralized facilities and trained personnel, marginalizing healthcare access in developing countries and rural communities. These issues have led researchers to focus on developing portable and affordable diagnostics that can be deployed at the point-of-care (POC). Typically, HF biomarkers are measured in blood not saliva. Recently, our team correlated concentrations of salivary Galectin-3 (Gal-3) to outcomes in patients with HF. We have developed an analytical device which consists of an immunoassay based on a screen-printed carbon electrode (SPCE) to quantify Gal-3 levels in saliva samples. Using 10 μL of saliva, the proposed electrochemical immunoassay achieved a concentration dependent signal response in the clinically relevant range with a limit of detection of 9.66 ng/mL. In addition, the storage stability of the modified electrode was investigated, and only a 10.9% loss in current response over a 35-day period. The results of the immunoassay on the modified SPCEs suggest validity as a POC biosensor system for the management of HF., Competing Interests: Declaration of competing interest The authors declare that they have no known competing financial interests.
- Published
- 2024
- Full Text
- View/download PDF
41. Profiling salivary miRNA expression levels in Fanconi anemia patients - a pilot study.
- Author
-
Tang KD, Amenábar JM, Schussel JL, Torres-Pereira CC, Bonfim C, Dimitrova N, Hartel G, and Punyadeera C
- Subjects
- Humans, Pilot Projects, Biomarkers, Tumor, Squamous Cell Carcinoma of Head and Neck, MicroRNAs genetics, MicroRNAs metabolism, Carcinoma, Squamous Cell genetics, Fanconi Anemia genetics, Mouth Neoplasms genetics, Head and Neck Neoplasms
- Abstract
The overarching goal of this study is to predict the risk of developing oral squamous cell carcinoma (OSCC) in Fanconi anemia (FA) patients. We have compared the microRNA (miRNA, miR) expression levels in saliva samples from FA patients (n = 50) who are at a low-moderate and/or high risk of developing OSCC to saliva samples from healthy controls (n = 16). The miRNA expression levels in saliva samples were quantified using qPCR. We observed that miR-744, miR-150-5P, and miR-146B-5P had the best discriminatory capacity between FA patients and controls, with an area under the curve (AUC) of 94.0%, 92.9% and 85.3%, respectively. Our data suggest that miR-1, miR-146B-5P, miR-150-5P, miR-155-5P, and miR-744 could be used as panel to predict the risk of developing OSCC in FA patients, with a 89.3% sensitivity and a 68.2% specificity (AUC = 81.5%). Our preliminary data support the notion that the expression levels of salivary miRNAs have the potential to predict the risk of developing OSCC in FA patients and in the future may reduce deaths associated with OSCC., (© 2023. The Author(s).)
- Published
- 2024
- Full Text
- View/download PDF
42. Prognostic utility of serum NT-proBNP (fragments 1-76aa and 13-71aa) and galectin-3 in predicting death and re-hospitalisation due to cardiovascular events in patients with heart failure.
- Author
-
Zhang X, Wan Y, Karunathilaka N, Chan W, Kostner K, Hartel G, Coats AJS, Atherton JJ, and Punyadeera C
- Subjects
- Humans, Prognosis, Natriuretic Peptide, Brain, Peptide Fragments, Biomarkers, Hospitalization, Galectin 3, Heart Failure
- Abstract
Patients with heart failure (HF) are at a higher risk of rehospitalisation. In this study, we investigated the prognostic utility of galectin-3 (Gal-3) and NT-proBNP fragments (1-76aa and 13-71aa) as biomarkers to predict outcomes for patients with HF. We collected blood samples from patients with HF (n = 101). Gal-3 and NT-proBNP fragments (1-76aa and 13-71aa) concentrations were measured by immunoassay. Survival analysis and Cox proportional regression models were used to determine the prognostic utility of Gal-3 and NT-proBNP fragments. In patients with increased baseline levels of NT-proBNP
1-76 the time to primary endpoint (cardiovascular death or re-hospitalisation) was significantly shorter (p = 0.0058), but not in patient with increased baseline levels of Gal-3 or NTproBNP13-71 . Patients with increased levels of NT-proBNP13-71aa at 1 month showed reduced time to the primary endpoint (p = 0.0123). Our findings demonstrated that Gal-3 and NT-proBNP can be used as prognostic biomarkers to stratify patients with HF., (© 2023. The Author(s).)- Published
- 2024
- Full Text
- View/download PDF
43. A comparison between mutational profiles in tumour tissue DNA and circulating tumour DNA in head and neck squamous cell carcinoma - A systematic review.
- Author
-
Huang X, Leo P, Jones L, Duijf PHG, Hartel G, Kenny L, Vasani S, and Punyadeera C
- Subjects
- Humans, Class I Phosphatidylinositol 3-Kinases genetics, Biomarkers, Tumor genetics, Biomarkers, Tumor blood, Tumor Suppressor Protein p53 genetics, Receptor, Notch1 genetics, DNA, Neoplasm genetics, DNA, Neoplasm blood, Cyclin-Dependent Kinase Inhibitor p16 genetics, Cadherins, Circulating Tumor DNA genetics, Circulating Tumor DNA blood, Squamous Cell Carcinoma of Head and Neck genetics, Squamous Cell Carcinoma of Head and Neck blood, Head and Neck Neoplasms genetics, Head and Neck Neoplasms blood, Mutation genetics
- Abstract
Background: Head and neck cancer is the seventh most common malignancy globally. Head and neck squamous cell carcinoma (HNSCC) originates from squamous cells and 90% of HNC are HNSCC. The gold standard for diagnosing HNSCC is tissue biopsy. However, given tumour heterogeneity, biopsies may miss important cancer-associated molecular signatures, and more importantly, after the tumour is excised, there is no means of tracking response to treatment in patients. Captured under liquid biopsy, circulating tumour DNA (ctDNA), may identify in vivo molecular genotypes and complements tumour tissue analysis in cancer management. A systematic search was conducted in PubMed, Embase, Scopus and the Cochran Library between 2012 to early 2023 on ctDNA in HNSCC using publications written in English. We summarise 20 studies that compared mutational profiles between tumour tissue DNA (tDNA) and ctDNA, using a cohort of 631 HNSCC patients and 139 controls. Among these studies, the concordance rates varied greatly and the most mutated and the most concordant gene was TP53, followed by PIK3CA, CDKN2A, NOTCH1 and FAT1. Concordant variants were mainly found in Stage IV tumours, and the mutation type is mostly single nucleotide variants (SNV). We conclude that, as a biomarker for HNSCC, ctDNA demonstrates great promise as it recapitulates tumour genotypes, however additional multi-central trials are needed., Competing Interests: Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (Copyright © 2023 The Authors. Published by Elsevier B.V. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
44. Detecting salivary host and microbiome RNA signature for aiding diagnosis of oral and throat cancer.
- Author
-
Banavar G, Ogundijo O, Julian C, Toma R, Camacho F, Torres PJ, Hu L, Chandra T, Piscitello A, Kenny L, Vasani S, Batstone M, Dimitrova N, Vuyisich M, Amar S, and Punyadeera C
- Subjects
- Adult, Humans, Pharynx pathology, Squamous Cell Carcinoma of Head and Neck, RNA, Saliva, Biomarkers, Tumor, Mouth Neoplasms diagnosis, Mouth Neoplasms genetics, Mouth Neoplasms pathology, Carcinoma, Squamous Cell pathology, Head and Neck Neoplasms
- Abstract
Objective: Oral squamous cell carcinoma (OSCC) and oropharyngeal squamous cell carcinoma (OPSCC) can go undetected resulting in late detection and poor outcomes. We describe the development and validation of CancerDetect for Oral & Throat cancer™ (CDOT), to detect markers of OSCC and/or OPSCC within a high-risk population., Material and Methods: We collected saliva samples from 1,175 individuals who were 50 years or older, or adults with a tobacco use history. 945 of those were used to train a classifier using machine learning methods, resulting in a salivary microbial and human metatranscriptomic signature. The classifier was then independently validated on the 230 remaining samples prospectively collected and unseen by the classifier, consisting of 20 OSCC (all stages), 76 OPSCC (all stages), and 134 negatives (including 14 pre-malignant)., Results: On the validation cohort, the specificity of the CDOT test was 94 %, sensitivity was 90 % for participants with OSCC, and 84.2 % for participants with OPSCC. Similar classification results were observed among people in early stage (stages I & II) vs late stage (stages III & IV)., Conclusions: CDOT is a non-invasive test that can be easily administered in dentist offices, primary care centres and specialised cancer clinics for early detection of OPSCC and OSCC. This test, having received FDA's breakthrough designation for accelerated review, has the potential to enable early diagnosis, saving lives and significantly reducing healthcare expenditure., Competing Interests: Declaration of Competing Interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Several authors (GB, OO, CJ, RT, FC, PJT, LK, ND, LH and MV) are employees of Viome Life Sciences, Inc. GB, OO, RT, MV, CP are co-inventors on a patent for a metatranscriptomics-based saliva test for OSCC and OPSCC., (Copyright © 2023 Elsevier Ltd. All rights reserved.)
- Published
- 2023
- Full Text
- View/download PDF
45. Proteome profiling of salivary small extracellular vesicles in glioblastoma patients.
- Author
-
Müller Bark J, Trevisan França de Lima L, Zhang X, Broszczak D, Leo PJ, Jeffree RL, Chua B, Day BW, and Punyadeera C
- Subjects
- Humans, Proteome metabolism, Biomarkers metabolism, Glioblastoma pathology, Extracellular Vesicles metabolism, Extracellular Vesicles pathology, Glioma pathology
- Abstract
Background: Extracellular vesicles (EVs) play a critical role in intercellular communication under physiological and pathological conditions, including cancer. EVs cargo reflects their cell of origin, suggesting their utility as biomarkers. EVs are detected in several biofluids, and their ability to cross the blood-brain barrier has highlighted their potential as prognostic and diagnostic biomarkers in gliomas, including glioblastoma (GBM). Studies have demonstrated the potential clinical utility of plasma-derived EVs in glioma. However, little is known about the clinical utility of saliva-derived EVs in GBM., Methods: Small EVs were isolated from whole mouth saliva of GBM patients pre- and postoperatively. Isolation was performed using differential centrifugation and/or ultracentrifugation. EVs were characterized by concentration, size, morphology, and EVs cell-surface protein markers. Protein cargo in EVs was profiled using mass spectrometry., Results: There were no statistically significant differences in size and concentration of EVs derived from pre- and post GBM patients' saliva samples. A higher number of proteins were detected in preoperative samples compared to postoperative samples. The authors found four highly abundant proteins (aldolase A, 14-3-3 protein ε, enoyl CoA hydratase 1, and transmembrane protease serine 11B) in preoperative saliva samples from GBM patients with poor outcomes. Functional enrichment analysis of pre- and postoperative saliva samples showed significant enrichment of several pathways, including those related to the immune system, cell cycle and programmed cell death., Conclusions: This study, for the first time, demonstrates the feasibility of isolating and characterizing small EVs from pre- and postoperative saliva samples from GBM patients. Preliminary findings encourage further large cohort validation studies on salivary small EVs to evaluate prognosis in GBM., (© 2023 The Authors. Cancer published by Wiley Periodicals LLC on behalf of American Cancer Society.)
- Published
- 2023
- Full Text
- View/download PDF
46. Circulating tumour DNA alterations: emerging biomarker in head and neck squamous cell carcinoma.
- Author
-
Huang X, Duijf PHG, Sriram S, Perera G, Vasani S, Kenny L, Leo P, and Punyadeera C
- Subjects
- Humans, Squamous Cell Carcinoma of Head and Neck diagnosis, Squamous Cell Carcinoma of Head and Neck genetics, Biomarkers, Tumor genetics, Prognosis, Circulating Tumor DNA genetics, Head and Neck Neoplasms diagnosis, Head and Neck Neoplasms genetics
- Abstract
Head and Neck cancers (HNC) are a heterogeneous group of upper aero-digestive tract cancer and account for 931,922 new cases and 467,125 deaths worldwide. About 90% of these cancers are of squamous cell origin (HNSCC). HNSCC is associated with excessive tobacco and alcohol consumption and infection with oncogenic viruses. Genotyping tumour tissue to guide clinical decision-making is becoming common practice in modern oncology, but in the management of patients with HNSCC, cytopathology or histopathology of tumour tissue remains the mainstream for diagnosis and treatment planning. Due to tumour heterogeneity and the lack of access to tumour due to its anatomical location, alternative methods to evaluate tumour activities are urgently needed. Liquid biopsy approaches can overcome issues such as tumour heterogeneity, which is associated with the analysis of small tissue biopsy. In addition, liquid biopsy offers repeat biopsy sampling, even for patients with tumours with access limitations. Liquid biopsy refers to biomarkers found in body fluids, traditionally blood, that can be sampled to provide clinically valuable information on both the patient and their underlying malignancy. To date, the majority of liquid biopsy research has focused on blood-based biomarkers, such as circulating tumour DNA (ctDNA), circulating tumour cells (CTCs), and circulating microRNA. In this review, we will focus on ctDNA as a biomarker in HNSCC because of its robustness, its presence in many body fluids, adaptability to existing clinical laboratory-based technology platforms, and ease of collection and transportation. We will discuss mechanisms of ctDNA release into circulation, technological advances in the analysis of ctDNA, ctDNA as a biomarker in HNSCC management, and some of the challenges associated with translating ctDNA into clinical and future perspectives. ctDNA provides a minimally invasive method for HNSCC prognosis and disease surveillance and will pave the way in the future for personalized medicine, thereby significantly improving outcomes and reducing healthcare costs., (© 2023. National Science Council of the Republic of China (Taiwan).)
- Published
- 2023
- Full Text
- View/download PDF
47. Method optimisation to enrich small extracellular vesicles from saliva samples.
- Author
-
Jangholi A, Bark JM, Trevisan França de Lima L, Lima LG, Möller A, Kenny L, Vasani S, Rao S, Dolcetti R, and Punyadeera C
- Subjects
- Humans, Saliva, Extracellular Vesicles
- Published
- 2023
- Full Text
- View/download PDF
48. Post-treatment 18F-fludeoxyglocuse-positron emission tomography in human papillomavirus-associated oropharyngeal cancer.
- Author
-
Liu ZY, Khoo D, Hartel G, Punyadeera C, and Vasani S
- Subjects
- Humans, Human Papillomavirus Viruses, Fluorodeoxyglucose F18, Retrospective Studies, Prospective Studies, Neoplasm Recurrence, Local diagnostic imaging, Positron-Emission Tomography methods, Positron Emission Tomography Computed Tomography methods, Carcinoma, Squamous Cell diagnostic imaging, Carcinoma, Squamous Cell therapy, Carcinoma, Squamous Cell pathology, Papillomavirus Infections complications, Papillomavirus Infections diagnostic imaging, Papillomavirus Infections pathology, Oropharyngeal Neoplasms diagnostic imaging, Oropharyngeal Neoplasms therapy, Oropharyngeal Neoplasms pathology, Head and Neck Neoplasms complications
- Abstract
Background: Human papillomavirus association has changed the landscape of treatment for oropharyngeal squamous cell carcinoma; it remains to be seen whether current post-treatment surveillance schedules are effective., Objective: Evaluate whether post-treatment surveillance of oropharyngeal cancer through FDG-PET imaging is modified by human papillomavirus association., Methods: A prospective cohort analysis of retrospective data was conducted for patients undergoing treatment of oropharyngeal cancer between 2016 and 2018. This study was conducted at a single large tertiary referral center in Brisbane, Australia., Results: Two-hundred and twenty-four patients were recruited for the purposes of the study, 193 (86%) with HPV-associated disease. In this cohort FDG-PET had a sensitivity of 48.3%, specificity of 72.6%, positive predictive value of 23.7%, and negative predictive value of 88.8% in detecting disease recurrence., Conclusions: FDG-PET in HPV-associated oropharyngeal cancer has significantly lower positive predictive value when compared to non-HPV-associated oropharyngeal cancer. Caution should be used when interpreting positive post-treatment FDG-PET., (© 2023 Wiley Periodicals LLC.)
- Published
- 2023
- Full Text
- View/download PDF
49. Salivary micro RNAs as biomarkers for oropharyngeal cancer.
- Author
-
Ekanayake Weeramange C, Tang KD, Barrero RA, Hartel G, Liu Z, Ladwa R, Langton-Lockton J, Frazer I, Kenny L, Vasani S, and Punyadeera C
- Subjects
- Humans, Biomarkers, Tumor genetics, Biomarkers, Tumor metabolism, MicroRNAs genetics, Papillomavirus Infections complications, Papillomavirus Infections diagnosis, Oropharyngeal Neoplasms diagnosis, Oropharyngeal Neoplasms genetics, Head and Neck Neoplasms complications
- Abstract
Background: Despite the rising incidence, particularly of the human papillomavirus (HPV)-associated fraction of oropharyngeal cancer (OPC), there are no early detection methods for OPC. Considering the close association between saliva and head and neck cancers, this study was designed to investigate salivary micro RNA (miRNAs) associated with OPC, especially focusing on HPV-positive OPC., Methods: Saliva was collected from OPC patients at diagnosis and patients were clinically followed up ≤5 years. Salivary small RNA isolated from HPV-positive OPC patients (N = 6), and HPV-positive (N = 4) and negative controls (N = 6) were analysed by next-generation sequencing to identify dysregulated miRNAs. Discovered miRNAs were validated by quantitative PCR using two different assays in a separate cohort of patients (OPC = 91, controls = 92). The relative expression was calculated considering SNORD-96A as the normalizer. Candidate miRNAs with diagnostic and prognostic potential were evaluated by generalized logistic regression., Results: A panel consisting of nine miRNAs was identified to have the best diagnostic performance to discriminate HPV-positive OPC from HPV-positive controls (AUC- validation-1 = 94.8%, validation-2 = 98%). Further, a panel consisting of six miRNAs were identified to discriminate OPC from controls regardless of the HPV status (AUC- validation-1 = 77.2%, validation-2 = 86.7%). In addition, the downregulation of hsa-miR-7-5p was significantly associated with poor overall survival of OPC patients (HR = 0.638). A panel consisting of nine miRNAs were identified for the prediction of the overall survival of the OPC patients (log-rank test-p = 0.0008)., Conclusion: This study highlights that salivary miRNAs can play an essential role in the detection and prognostication of OPC., (© 2023 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.)
- Published
- 2023
- Full Text
- View/download PDF
50. A salivary biomarker panel to detect liver cirrhosis.
- Author
-
Trevisan França de Lima L, Crawford DHG, Broszczak DA, Zhang X, Bridle R K, and Punyadeera C
- Abstract
Limited access to diagnostic tests for liver fibrosis remains one of the main reasons for late diagnosis, especially in rural and remote communities. Saliva diagnostics is accessible with excellent patient compliance. The aim of this study was to develop a saliva-based diagnostic tool for liver fibrosis/cirrhosis. Salivary concentrations of hyaluronic acid (HA), tissue inhibitor of metalloproteinase-1 (TIMP-1), and α-2-macroglobulin (A2MG) were significantly increased (p < 0.05) in patients with liver fibrosis/cirrhosis. By combining these biomarkers, we developed the Saliva Liver Fibrosis (SALF) score, which identified patients with liver cirrhosis with an area under the receiver operating characteristic curve (AUROC) of 0.970 and 0.920 in a discovery and validation cohorts, respectively. The SALF score had a performance that was similar to that of the current Fibrosis-4 (AUROC:0.740) and Hepascore (AUROC:0.979). We demonstrated the clinical utility of saliva to diagnose liver fibrosis/cirrhosis with a potential to improve the screening for cirrhosis in asymptomatic populations., Competing Interests: Some of the authors are inventors on a provisional patent application that has been filed to the Australian Patent Office (reference 2022901434). The authors have no relevant financial or non-financial interests to disclose., (© 2023 The Authors.)
- Published
- 2023
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.